
|Videos|May 9, 2017
Dr. Meinhardt on the Impact of the RESORCE Study in HCC
Author(s)Gerold Meinhardt, MD
Gerold Meinhardt, MD, global clinical leader at Bayer Pharmaceuticals, discusses the impact of the RESORCE trial in hepatocellular carcinoma.
Advertisement
Gerold Meinhardt, MD, global clinical leader at Bayer Pharmaceuticals, discusses the impact of the RESORCE trial in hepatocellular carcinoma (HCC).
Regorafenib (Stivarga), was recently approved by the FDA for use in patients with HCC that have progressed on Sorafenib (Nexavar). This approval was based on the findings of the phase III RESORCE trial, which showed a significant improvement in survival with a manageable safety profile.
Meinhardt says that this trial provides hope for new therapies in a disease that is historically difficult to treat.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































